ClinicalTrials.gg
CompletedNCT01594281PRIDEUpdated Mar 15, 2019Results posted

Multicenter 12 Months Clinical Study to Evaluate Efficacy and Safety of Ranibizumab Alone or in Combination With Laser Photocoagulation vs. Laser Photocoagulation Alone in Proliferative Diabetic Retinopathy (PRIDE)

A Phase 2 interventional study of Ranibizumab 0.5 mg and Panretinal laser photocoagulation in Proliferative Diabetic Retinopathy (PDR), sponsored by Novartis Pharmaceuticals. Completed at 23 sites in Germany. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2019-03-15.

Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
107
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 34 studies testing ranibizumab in Diabetic Retinopathy — 2 open to participants now, 2 under way, 1 of them phase 3. Ranibizumab · Diabetic Retinopathy.

Enrollment
11th of 34
107 · median 57
Started
2012
with 2 others
Phase 2
9 of 34
none open now
Registered
16th of 34
by date
Lead sponsor
6 of 34
Novartis Pharmaceuticals

Among the 34 studies testing ranibizumab in Diabetic Retinopathy, this one is the 11th largest by enrollment, is one of 3 that started in 2012, is one of 9 in phase 2, and was the 16th registered.

Diabetic Retinopathy

779 studies on the registry are indexed under Diabetic Retinopathy; 143 are open to participants now.

Browse Diabetic Retinopathy studies →

Open to participants now

2 of the 34 studies testing ranibizumab in Diabetic Retinopathy are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About ranibizumab

Ranibizumab: first FDA approval 2006 (LUCENTIS), first EMA approval 2007. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 92 Diabetic Retinopathy studies recruiting now, 60 (65%) set no upper age limit and 10 (11%) stop at 75 or younger; 8 take children under 18; 29 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 34 studies testing ranibizumab in Diabetic Retinopathy, or all of them as a file.
02

Study summary

The purpose of this study was to assess the efficacy and safety of the anti-Vascular Endothelial Growth Factor (VEGF) agent ranibizumab (0.5 mg) with or without Panretinal laser photocoagulation (PRP) compared to PRP alone in patients with Proliferative Diabetic Retinopathy (PDR).

Read the detailed description

A 12-month core phase was followed by a 12-month observational follow-up phase (physician's routine), for a planned individual study duration of 24-25 months. A separate informed consent was signed for the 12-month observational follow-up phase. This study was conducted in Germany.

03

Conditions studied

  • Proliferative Diabetic Retinopathy (PDR)

Browse trials for

Keywords

  • Panretinal photocoagulation
  • Ranibizumab
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Proliferative Diabetic Retinopathy
  • Best Corrected Visual Acuity (BCVA) in study eye of at least 20 Early Treatment Diabetic Retinopathy Study (ETDRS) letters (20/400)
  • Type 1 or type 2 diabetes under medical surveillance / with stabilized treatment

Exclusion criteria

Exclusion Criteria:

  • Proliferative vitreoretinopathy in study eye
  • macular edema (CSME) in the study eye
  • Clinically non significant macular edema (CNSME) that is likely to develop to CSME in the study eye
  • Uncontrolled glaucoma in either eye
  • Other protocol-specified conditions
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
107 participants (actual)

Study arms

  • Experimental
    Ranibizumab mono

    Interventional Core Phase: One intravitreal injection of ranibizumab 0.5 mg to the study eye monthly until stability regarding morphological parameters is confirmed (ie, no further improvement of morphology or no worsening of morphology for 3 consecutive months)

    Drug: Ranibizumab 0.5 mg

  • Active comparator
    PRP mono

    Interventional Core Phase: Panretinal laser photocoagulation (PRP) treatment administered to the study eye in accordance with the modified diabetic retinopathy study (DRS) guidelines for panretinal laser photocoagulation procedures

    Procedure: Panretinal laser photocoagulation

  • Experimental
    Ranibizumab+PRP

    Interventional Core Phase: Ranibizumab 0.5 mg as described for the ranibizumab mono arm and PRP treatment as described for the PRP mono arm until stability regarding morphological parameters is confirmed

    Drug: Ranibizumab 0.5 mg · Procedure: Panretinal laser photocoagulation

Interventions

  • Pre-filled syringe for intravitreal injection

    Also known as: Lucentis®, RFB002

  • ProcedurePanretinal laser photocoagulation

    PRP treatment following DRS guidelines

    Also known as: PRP

06

What researchers measure

Primary outcomes

  1. Change From Baseline in Area of Neovascularizations (NVs) at End of Core Study (EOCS)

    The area of neovascularizations (NV) was assessed by a central reading center via fluorescein angiography (FA) images. The area of NV was calculated as the sum of area of neovascularization of the disc (NVD) and neovascularization elsewhere (NVE) and was recorded in square millimeters. A higher positive change value may indicate a greater formation of new, abnormal blood vessels and thus disease progression. One eye (study eye) contributed to the analysis.

    Time frame: Baseline, EOCS

Secondary outcomes

  1. Change From Baseline in Area of Neovascularizations (NVs) at Month 3

    The area of neovascularizations (NV) was assessed by a central reading center via fluorescein angiography (FA) images. The area of NV was calculated as the sum of area of neovascularization of the disc (NVD) and neovascularization elsewhere (NVE) and was recorded in square millimeters. A higher positive change value may indicate a greater formation of new, abnormal blood vessels and thus disease progression. One eye (study eye) contributed to the analysis.

    Time frame: Baseline, Month 3

  2. Best Corrected Visual Acuity (BCVA) (ETDRS Letters) at EOCS

    BCVA was assessed using Early Treatment Diabetic Retinopathy Study (ETDRS)-like charts at a testing distance of 4 meters. A higher number of ETDRS letters may indicate better visual acuity. One eye (study eye) contributed to the analysis.

    Time frame: EOCS

  3. Percentage of Patients With Change From Baseline in BCVA (ETDRS Letters) at EOCS

    BCVA was assessed using Early Treatment Diabetic Retinopathy Study (ETDRS)-like charts at a testing distance of 4 meters. No clinically relevant change was defined as \<5 letters gain or loss. A higher positive change value may indicate a greater improvement in visual acuity. One eye (study eye) contributed to the analysis.

    Time frame: Baseline, EOCS

  4. Number of Patients With Change From Baseline in ETDRS Severity Grade of Diabetic Retinopathy (DR) at EOCS

    The severity level of diabetic retinopathy was determined using the ETDRS severity scale. However, in contrast to the original ETDRS severity scale, wide field fluorescein angiography images were used in addition to color fundus photography for identification of NVs and prior PRP treatment was not considered for determining the severity level. Eyes could be graded in the following classes: "DR absent" (10), "questionable DR" (14,15), "NPDR" (20-53), "mild PDR" (60-61), "moderate PDR" (65), "high risk PDR" (71-75), "advanced PDR" (81-85) and "cannot grade" (90). One eye (study eye) contributed to the analysis. No statistical analysis was conducted for ≥ 1 class deterioration or ≥ 2 class deterioration from Baseline at EOCS because ratios could not be calculated in case of zero frequencies in at least one of the three treatment groups.

    Time frame: Baseline, EOCS

  5. Change From Baseline in Central Subfield Thickness at EOCS

    Central subfield retinal thickness was assessed by a central reading center using Optical Coherence Tomography images. A positive change value may indicate disease progression. One eye (study eye) contributed to the analysis.

    Time frame: Baseline, EOCS

  6. Change From Baseline in Foveal Center Point Retinal Thickness at EOCS

    Foveal center point retinal thickness was assessed by a central reading center using Optical Coherence Tomography images. A positive change value may indicate disease progression. One eye (study eye) contributed to the analysis.

    Time frame: Baseline, EOCS

  7. Number of Ranibizumab Injections Until EOCS

    The total number of ranibizumab injections until EOCS was calculated. One eye (study eye) contributed to the analysis. No statistical analysis was conducted.

    Time frame: Baseline to EOCS

  8. Number of PRP Laser Spots Until EOCS

    The total number of PRP laser spots from baseline until EOCS was calculated. One eye (study eye) contributed to the analysis. No statistical analysis was conducted.

    Time frame: Baseline to EOCS

07

Results

Posted Mar 15, 2019

Participant flow

Patients were screened for eligibility at 23 German study sites and randomized at 22 of the 23 sites.

Interventional Core Phase
Participant flow — Interventional Core Phase
MilestoneRanibizumab MonoPRP MonoRanibizumab+PRP
Started363636
Full analysis set (fas)353536
Completed292628
Not completed7108
Withdrew: Protocol deviation100
Withdrew: Subject withdrew consent011
Withdrew: Death112
Withdrew: Lost to follow-up141
Withdrew: Adverse event444
Non-Interventional Follow Up Phase
Participant flow — Non-Interventional Follow Up Phase
MilestoneRanibizumab MonoPRP MonoRanibizumab+PRP
Started282125
Follow up set (fus)282025
Completed251923
Not completed322
Withdrew: Lost to follow-up220
Withdrew: Administrative problems001
Withdrew: Subject withdrew consent101

Outcome measures

PrimaryChange From Baseline in Area of Neovascularizations (NVs) at End of Core Study (EOCS)

The area of neovascularizations (NV) was assessed by a central reading center via fluorescein angiography (FA) images. The area of NV was calculated as the sum of area of neovascularization of the disc (NVD) and neovascularization elsewhere (NVE) and was recorded in square millimeters. A higher positive change value may indicate a greater formation of new, abnormal blood vessels and thus disease progression. One eye (study eye) contributed to the analysis.

Time frame:
Baseline, EOCS
Reported as:
Mean · square millimeters
Change From Baseline in Area of Neovascularizations (NVs) at End of Core Study (EOCS)
square millimetersRanibizumab MonoPRP MonoRanibizumab+PRP
Change From Baseline in Area of Neovascularizations (NVs) at End of Core Study (EOCS)-4.6 ± 11.3-0.9 ± 3.9-1.7 ± 3.0
Statistical analysis
  • Ranibizumab Mono vs PRP Mono · ANCOVA · p = 0.0344 · Least squares mean difference: -2.8 · 95% CI -5.4 to -0.2
  • Ranibizumab Mono vs Ranibizumab+PRP · ANCOVA · p = 0.3809 · Least squares mean difference: -1.2 · 95% CI -3.8 to 1.5
  • PRP Mono vs Ranibizumab+PRP · ANCOVA · p = 0.2113 · Least squares mean difference: 1.7 · 95% CI -1.0 to 4.3
SecondaryChange From Baseline in Area of Neovascularizations (NVs) at Month 3

The area of neovascularizations (NV) was assessed by a central reading center via fluorescein angiography (FA) images. The area of NV was calculated as the sum of area of neovascularization of the disc (NVD) and neovascularization elsewhere (NVE) and was recorded in square millimeters. A higher positive change value may indicate a greater formation of new, abnormal blood vessels and thus disease progression. One eye (study eye) contributed to the analysis.

Time frame:
Baseline, Month 3
Reported as:
Mean · square millimeters
Change From Baseline in Area of Neovascularizations (NVs) at Month 3
square millimetersRanibizumab MonoPRP MonoRanibizumab+PRP
Change From Baseline in Area of Neovascularizations (NVs) at Month 3-5.9 ± 12.7-0.7 ± 2.8-2.7 ± 3.9
Statistical analysis
  • Ranibizumab Mono vs PRP Mono · ANCOVA · p = 0.0081 · Least squares mean difference: -2.4 · 95% CI -4.2 to -0.6
  • Ranibizumab Mono vs Ranibizumab+PRP · ANCOVA · p = 0.7494 · Least squares mean difference: -0.3 · 95% CI -2.0 to 1.5
  • PRP Mono vs Ranibizumab+PRP · ANCOVA · p = 0.0175 · Least squares mean difference: 2.1 · 95% CI 0.4 to 3.9
SecondaryBest Corrected Visual Acuity (BCVA) (ETDRS Letters) at EOCS

BCVA was assessed using Early Treatment Diabetic Retinopathy Study (ETDRS)-like charts at a testing distance of 4 meters. A higher number of ETDRS letters may indicate better visual acuity. One eye (study eye) contributed to the analysis.

Time frame:
EOCS
Reported as:
Mean · letters
Best Corrected Visual Acuity (BCVA) (ETDRS Letters) at EOCS
lettersRanibizumab MonoPRP MonoRanibizumab+PRP
Best Corrected Visual Acuity (BCVA) (ETDRS Letters) at EOCS84.4 ± 8.676.8 ± 17.078.9 ± 12.2
Statistical analysis
  • Ranibizumab Mono vs PRP Mono · ANCOVA · p = 0.0495 · Least squares mean difference: 5.5 · 95% CI 0.0 to 11.0
  • Ranibizumab Mono vs Ranibizumab+PRP · ANCOVA · p = 0.2767 · Least squares mean difference: 3.0 · 95% CI -2.5 to 8.5
  • PRP Mono vs Ranibizumab+PRP · ANCOVA · p = 0.3641 · Least squares mean difference: -2.5 · 95% CI -7.9 to 2.9
SecondaryPercentage of Patients With Change From Baseline in BCVA (ETDRS Letters) at EOCS

BCVA was assessed using Early Treatment Diabetic Retinopathy Study (ETDRS)-like charts at a testing distance of 4 meters. No clinically relevant change was defined as \<5 letters gain or loss. A higher positive change value may indicate a greater improvement in visual acuity. One eye (study eye) contributed to the analysis.

Time frame:
Baseline, EOCS
Reported as:
Number · percentage of participants
Percentage of Patients With Change From Baseline in BCVA (ETDRS Letters) at EOCS
percentage of participantsRanibizumab MonoPRP MonoRanibizumab+PRP
≥15 letters gain from Baseline at EOCS0.02.90.0
≥10 letters gain from Baseline at EOCS5.711.48.3
≥5 letters gain from Baseline at EOCS31.420.013.9
No clinically relevant change from Baseline51.442.961.1
≥5 letters loss from Baseline at EOCS17.137.125.0
≥10 letters loss from Baseline at EOCS11.411.48.3
≥15 letters loss from Baseline at EOCS2.98.62.8
Statistical analysis
  • Ranibizumab Mono vs PRP Mono · Regression, Logistic · p = 0.4019 · Odds ratio (or): 0.470 · 95% CI 0.080 to 2.749
  • Ranibizumab Mono vs PRP Mono · Regression, Logistic · p = 0.2772 · Odds ratio (or): 1.833 · 95% CI 0.614 to 5.471
  • Ranibizumab Mono vs PRP Mono · Regression, Logistic · p = 0.4731 · Odds ratio (or): 1.412 · 95% CI 0.55 to 3.622
  • Ranibizumab Mono vs PRP Mono · Regression, Logistic · p = 0.065 · Odds ratio (or): 0.350 · 95% CI 0.155 to 1.068
  • Ranibizumab Mono vs PRP Mono · Regression, Logistic · p = 1.000 · Odds ratio (or): 1.000 · 95% CI 0.229 to 4.361
  • Ranibizumab Mono vs PRP Mono · Regression, Logistic · p = 0.3261 · Odds ratio (or): 0.314 · 95% CI 0.031 to 3.173
  • Ranibizumab Mono vs Ranibizumab+PRP · Regression, Logistic · p = 0.6680 · Odds ratio (or): 0.667 · 95% CI 0.104 to 4.253
  • Ranibizumab Mono vs Ranibizumab+PRP · Regression, Logistic · p = 0.0838 · Odds ratio (or): 2.842 · 95% CI 0.870 to 9.283
  • Ranibizumab Mono vs Ranibizumab+PRP · Regression, Logistic · p = 0.4116 · Odds ratio (or): 0.674 · 95% CI 0.263 to 1.729
  • Ranibizumab Mono vs Ranibizumab+PRP · Regression, Logistic · p = 0.4197 · Odds ratio (or): 0.621 · 95% CI 0.195 to 1.977
  • Ranibizumab Mono vs Ranibizumab+PRP · Regression, Logistic · p = 0.6632 · Odds ratio (or): 1.419 · 95% CI 0.294 to 6.856
  • Ranibizumab Mono vs Ranibizumab+PRP · Regression, Logistic · p = 0.9839 · Odds ratio (or): 1.029 · 95% CI 0.062 to 17.127
  • PRP Mono vs Ranibizumab+PRP · Regression, Logistic · p = 0.6630 · Odds ratio (or): 1.419 · 95% CI 0.294 to 6.858
  • PRP Mono vs Ranibizumab+PRP · Regression, Logistic · p = 0.4941 (P-value was calculated as a point estimate.) · Odds ratio (or): 1.550 · 95% CI 0.441 to 5.444
  • PRP Mono vs Ranibizumab+PRP · Regression, Logistic · p = 0.1259 · Odds ratio (or): 0.477 · 95% CI 0.185 to 1.231
  • PRP Mono vs Ranibizumab+PRP · Regression, Logistic · p = 0.2710 · Odds ratio (or): 1.773 · 95% CI 0.640 to 4.913
  • PRP Mono vs Ranibizumab+PRP · Regression, Logistic · p = 0.6632 · Odds ratio (or): 1.419 · 95% CI 0.294 to 6.856
  • PRP Mono vs Ranibizumab+PRP · Regression, Logistic · p = 0.3140 · Odds ratio (or): 3.282 · 95% CI 0.325 to 33.171
SecondaryNumber of Patients With Change From Baseline in ETDRS Severity Grade of Diabetic Retinopathy (DR) at EOCS

The severity level of diabetic retinopathy was determined using the ETDRS severity scale. However, in contrast to the original ETDRS severity scale, wide field fluorescein angiography images were used in addition to color fundus photography for identification of NVs and prior PRP treatment was not considered for determining the severity level. Eyes could be graded in the following classes: "DR absent" (10), "questionable DR" (14,15), "NPDR" (20-53), "mild PDR" (60-61), "moderate PDR" (65), "high risk PDR" (71-75), "advanced PDR" (81-85) and "cannot grade" (90). One eye (study eye) contributed to the analysis. No statistical analysis was conducted for ≥ 1 class deterioration or ≥ 2 class deterioration from Baseline at EOCS because ratios could not be calculated in case of zero frequencies in at least one of the three treatment groups.

Time frame:
Baseline, EOCS
Reported as:
Number · participants
Number of Patients With Change From Baseline in ETDRS Severity Grade of Diabetic Retinopathy (DR) at EOCS
participantsRanibizumab MonoPRP MonoRanibizumab+PRP
≥ 1 class improvement from Baseline at EOCS10913
≥ 2 class improvement from Baseline at EOCS225
≥ 1 class deterioration from Baseline at EOCS201
≥ 2 class deterioration from Baseline at EOCS000
Statistical analysis
  • Ranibizumab Mono vs PRP Mono · Regression, Logistic · p = 0.9918 · Odds ratio (or): 0.994 · 95% CI 0.327 to 3.026
  • Ranibizumab Mono vs Ranibizumab+PRP · Regression, Logistic · p = 0.3595 · Odds ratio (or): 0.607 · 95% CI 0.209 to 1.765
  • PRP Mono vs Ranibizumab+PRP · Regression, Logistic · p = 0.3787 · Odds ratio (or): 0.611 · 95% CI 0.204 to 1.830
  • Ranibizumab Mono vs PRP Mono · Regression, Logistic · p = 0.9097 · Odds ratio (or): 0.889 · 95% CI 0.116 to 6.806
  • Ranibizumab Mono vs Ranibizumab+PRP · Regression, Logistic · p = 0.2230 · Odds ratio (or): 0.341 · 95% CI 0.060 to 1.925
  • PRP Mono vs Ranibizumab+PRP · Regression, Logistic · p = 0.2792 · Odds ratio (or): 0.383 · 95% CI 0.068 to 2.177
SecondaryChange From Baseline in Central Subfield Thickness at EOCS

Central subfield retinal thickness was assessed by a central reading center using Optical Coherence Tomography images. A positive change value may indicate disease progression. One eye (study eye) contributed to the analysis.

Time frame:
Baseline, EOCS
Reported as:
Mean · micrometer
Change From Baseline in Central Subfield Thickness at EOCS
micrometerRanibizumab MonoPRP MonoRanibizumab+PRP
Change From Baseline in Central Subfield Thickness at EOCS-6.0 ± 15.136.2 ± 55.917.6 ± 46.7
Statistical analysis
  • Ranibizumab Mono vs PRP Mono · ANCOVA · p = 0.0003 · Least squares mean difference: -40.7 · 95% CI -62.1 to -19.3
  • Ranibizumab Mono vs Ranibizumab+PRP · ANCOVA · p = 0.0357 · Least squares mean difference: -22.9 · 95% CI -44.2 to -1.6
  • PRP Mono vs Ranibizumab+PRP · ANCOVA · p = 0.1034 · Least squares mean difference: 17.8 · 95% CI -3.7 to 39.3
SecondaryChange From Baseline in Foveal Center Point Retinal Thickness at EOCS

Foveal center point retinal thickness was assessed by a central reading center using Optical Coherence Tomography images. A positive change value may indicate disease progression. One eye (study eye) contributed to the analysis.

Time frame:
Baseline, EOCS
Reported as:
Mean · micrometer
Change From Baseline in Foveal Center Point Retinal Thickness at EOCS
micrometerRanibizumab MonoPRP MonoRanibizumab+PRP
Change From Baseline in Foveal Center Point Retinal Thickness at EOCS-4.7 ± 21.248.1 ± 83.725.5 ± 53.5
Statistical analysis
  • Ranibizumab Mono vs PRP Mono · ANCOVA · p = 0.0007 · Least squares mean difference: -51.7 · 95% CI -81.1 to -22.3
  • Ranibizumab Mono vs Ranibizumab+PRP · ANCOVA · p = 0.0542 · Least squares mean difference: -28.9 · 95% CI -58.4 to 0.5
  • PRP Mono vs Ranibizumab+PRP · ANCOVA · p = 0.1288 · Least squares mean difference: 22.8 · 95% CI -6.7 to 52.3
SecondaryNumber of Ranibizumab Injections Until EOCS

The total number of ranibizumab injections until EOCS was calculated. One eye (study eye) contributed to the analysis. No statistical analysis was conducted.

Time frame:
Baseline to EOCS
Reported as:
Mean · injections
Number of Ranibizumab Injections Until EOCS
injectionsRanibizumab MonoPRP MonoRanibizumab+PRP
Number of Ranibizumab Injections Until EOCS5.2 ± 2.3NA ± NA5.0 ± 2.2
SecondaryNumber of PRP Laser Spots Until EOCS

The total number of PRP laser spots from baseline until EOCS was calculated. One eye (study eye) contributed to the analysis. No statistical analysis was conducted.

Time frame:
Baseline to EOCS
Reported as:
Mean · PRP laser spots
Number of PRP Laser Spots Until EOCS
PRP laser spotsRanibizumab MonoPRP MonoRanibizumab+PRP
Number of PRP Laser Spots Until EOCSNA ± NA1919.4 ± 673.11670.0 ± 568.4

Adverse events

Collected over Adverse Events (AEs) were collected from time of informed consent until 4 weeks after the patient has stopped study participation (approximately 2 years).. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Ranibizumab Mono Until Month 121/35 (2.9%)8/35 (22.9%)34/35 (97.1%)
PRP Mono Until Month 121/35 (2.9%)11/35 (31.4%)29/35 (82.9%)
Ranibizumab+PRP Until Month 122/36 (5.6%)16/36 (44.4%)34/36 (94.4%)
Ranibizumab Mono Month 12 to 240/28 (0%)5/28 (17.9%)21/28 (75%)
PRP Mono Month 12 to 240/20 (0%)5/20 (25%)12/20 (60%)
Ranibizumab+PRP Month 12 to 240/25 (0%)11/25 (44%)21/25 (84%)
Most frequent serious events
Showing 10 of 74
Most frequent serious events
EventRanibizumab Mono Until Month 12PRP Mono Until Month 12Ranibizumab+PRP Until Month 12Ranibizumab Mono Month 12 to 24PRP Mono Month 12 to 24Ranibizumab+PRP Month 12 to 24
DIABETIC RETINOPATHY (Left eye)Eye disorders1/351/350/360/282/202/25
DIABETIC FOOT (Non-ocular)Skin and subcutaneous tissue disorders0/351/353/360/280/200/25
VITREOUS HAEMORRHAGE (Right eye)Eye disorders1/352/350/360/280/202/25
DIABETIC RETINOPATHY (Right eye)Eye disorders0/351/352/360/281/201/25
CEREBROVASCULAR ACCIDENT (Non-ocular)Nervous system disorders1/350/352/360/280/200/25
HEART VALVE STENOSIS (Non-ocular)Cardiac disorders0/350/350/360/281/200/25
TENDON RUPTURE (Non-ocular)Injury, poisoning and procedural complications0/350/350/360/281/200/25
BLOOD GLUCOSE FLUCTUATION (Non-ocular)Investigations0/350/351/360/281/200/25
PSYCHIATRIC DECOMPENSATION (Non-ocular)Psychiatric disorders0/350/350/360/281/200/25
CONGESTIVE CARDIOMYOPATHY (Non-ocular)Cardiac disorders0/350/350/360/280/201/25
Most frequent other events
Showing 10 of 91
Most frequent other events
EventRanibizumab Mono Until Month 12PRP Mono Until Month 12Ranibizumab+PRP Until Month 12Ranibizumab Mono Month 12 to 24PRP Mono Month 12 to 24Ranibizumab+PRP Month 12 to 24
RETINAL NEOVASCULARISATION (Right eye)Eye disorders12/353/3510/365/282/204/25
NASOPHARYNGITIS (Non-ocular)Infections and infestations7/3512/359/362/282/203/25
VISUAL ACUITY REDUCED (Left eye)Eye disorders5/353/3512/362/281/201/25
RETINAL NEOVASCULARISATION (Left eye)Eye disorders5/354/359/368/280/204/25
VITREOUS HAEMORRHAGE (Right eye)Eye disorders4/357/355/363/281/207/25
VISUAL ACUITY REDUCED (Right eye)Eye disorders7/359/355/363/283/201/25
MACULAR OEDEMA (Right eye)Eye disorders3/358/354/365/281/204/25
DIABETIC RETINOPATHY (Left eye)Eye disorders7/351/357/362/280/204/25
MACULAR OEDEMA (Left eye)Eye disorders5/354/354/362/284/203/25
RETINAL NEOVASCULARISATION (Both eyes)Eye disorders1/351/352/360/280/205/25

Baseline characteristics

Safety Set

Age, Continuous
Age, Continuous(Years)Ranibizumab MonoPRP MonoRanibizumab+PRPTotal
Mean52.5 ± 11.053.0 ± 12.155.0 ± 13.453.5 ± 12.1
Sex: Female, Male
Sex: Female, Male(Participants)Ranibizumab MonoPRP MonoRanibizumab+PRPTotal
Female1411833
Male21242873
Race and Ethnicity Not Collected
Race and Ethnicity Not Collected(Participants)Ranibizumab MonoPRP MonoRanibizumab+PRPTotal
Count of participants———0
08

Study locations

23 sites
  • Novartis Investigative Site
    Aachen, 52074, Germany
  • Novartis Investigative Site
    Augsburg, 86156, Germany
  • Novartis Investigative Site
    Berlin, 12203, Germany
  • Novartis Investigative Site
    Darmstadt, 64297, Germany
  • Novartis Investigative Site
    Duesseldorf, 40225, Germany
  • Novartis Investigative Site
    Essen, 45122, Germany
  • Novartis Investigative Site
    Freiburg, 79106, Germany
  • Novartis Investigative Site
    Glauchau, 08371, Germany
  • Novartis Investigative Site
    Gottingen, 37075, Germany
  • Novartis Investigative Site
    Hamburg, 20246, Germany
  • Novartis Investigative Site
    Hösbach, 63768, Germany
  • Novartis Investigative Site
    Karlsruhe, 76133, Germany
  • Novartis Investigative Site
    Koeln, 51109, Germany
  • Novartis Investigative Site
    Leipzig, 04103, Germany
  • Novartis Investigative Site
    Mainz, 55131, Germany
  • Novartis Investigative Site
    Marburg, 35039, Germany
  • Novartis Investigative Site
    Muenchen, 81675, Germany
  • Novartis Investigative Site
    Muenster, 48145, Germany
  • Novartis Investigative Site
    Muenster, 48149, Germany
  • Novartis Investigative Site
    München, 80336, Germany
  • Novartis Investigative Site
    Regensburg, 93042, Germany
  • Novartis Investigative Site
    Tübingen, 72076, Germany
  • Novartis Investigative Site
    Ulm, 89075, Germany
09

References and documents

Individual participant data

Plan to share: Undecided — Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations. This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com.

No publications or documents are linked to this record.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Dec 2012 to primary completion in Nov 2016, 47 months.

Results were first posted in Mar 2019, 2 years 3 months after primary completion.

Of 30 industry-sponsored phase 2 interventional studies under Diabetic Retinopathy, half reached primary completion within 30 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 37. This study's 47 months is above that.

Counting every sponsor, half of 43 studies reached it within 31 months; a quarter within 17 and three quarters within 37.

How these figures are worked out, and which studies are left out of them.

Registered
May 3, 2012
First posted
May 9, 2012
StartActual
Dec 11, 2012
Primary completionActual
Nov 30, 2016
CompletionActual
Dec 5, 2017
Results first posted
Mar 15, 2019
Last update
Mar 15, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 15, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01594281
Responsible party
Sponsor
First posted
May 9, 2012
Start date
Dec 11, 2012
Primary completion
Nov 30, 2016
Completion
Dec 5, 2017
Results posted
Mar 15, 2019
Last update
Mar 15, 2019

Study contacts

Novartis Pharmaceuticals
study director · Novartis Pharmaceuticals

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ranibizumab

Start the discussion